Compounds > bufuralol
Page last updated: 2024-08-25

bufuralol and nadp

bufuralol has been researched along with nadp in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aoyama, T; Gonzalez, FJ; Matsunaga, E; Meyer, UA; Zanger, UM; Zeugin, T1
Hardwick, JP; Meyer, UA; Vilbois, F; Zanger, UM1
Dong, MS; Gillam, EM; Guengerich, FP; Johnson, WW; Shimada, T; Yamazaki, H1
Fujita, K; Kamataki, T; Nakayama, K; Nohmi, T; Tsuruma, K; Yamada, M; Yamazaki, Y1
Fisher, MB; Foti, RS1
Ekman, S; Fransson-Steen, R; Hagbjörk, AL; Löfgren, S; Terelius, Y1
Cho, C; Fujiwara, R; Furge, LL; Glass, SM; Glista, MJ; Hicks, MJ; Kamath, SS; Martell, CM; Mills, JM; Osorio-Vasquez, V; Oswalt, AK1

Other Studies

7 other study(ies) available for bufuralol and nadp

ArticleYear
Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.
    The Journal of biological chemistry, 1990, Oct-05, Volume: 265, Issue:28

    Topics: Adrenergic beta-Antagonists; Animals; Cell Line; Chimera; Cloning, Molecular; Cytochrome P-450 Enzyme System; Debrisoquin; DNA, Neoplasm; Ethanolamines; Hydroxylation; Isoleucine; Kinetics; NADP; Rats; Recombination, Genetic; Spectrophotometry; Substrate Specificity; Vaccinia virus

1990
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
    Biochemistry, 1988, Jul-26, Volume: 27, Issue:15

    Topics: Benzene Derivatives; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Immunologic Techniques; Immunosorbent Techniques; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; NADP; Polymorphism, Genetic; Stereoisomerism; Substrate Specificity

1988
Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Archives of biochemistry and biophysics, 1997, Jun-15, Volume: 342, Issue:2

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; Chlorzoxazone; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Escherichia coli; Ethanolamines; Humans; Hydroxylation; Mixed Function Oxygenases; Mutation; NADP; Nifedipine; Oxidation-Reduction; Phospholipids; Recombinant Proteins; Testosterone; Theophylline; Tolbutamide; Warfarin

1997
Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Environmental and molecular mutagenesis, 2001, Volume: 38, Issue:4

    Topics: Alkylating Agents; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Ethanolamines; Genetic Engineering; Humans; Midazolam; Mixed Function Oxygenases; Mutagenicity Tests; NADP; NADPH-Ferrihemoprotein Reductase; Nitrosamines; Recombinant Proteins; Salmonella typhimurium; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases

2001
Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.
    Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:3

    Topics: Adrenergic beta-Antagonists; Blotting, Western; Cytochrome P-450 CYP2D6; Ethanolamines; Free Radical Scavengers; Humans; Hydroxylation; In Vitro Techniques; Isoenzymes; Microsomes, Liver; NADP; Protein Binding; Reactive Oxygen Species; Recombinant Proteins; Temperature

2004
Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
    Xenobiotica; the fate of foreign compounds in biological systems, 2004, Volume: 34, Issue:9

    Topics: Amiodarone; Animals; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Female; Humans; Kinetics; Lauric Acids; Male; Mephenytoin; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Microsomes, Liver; Mixed Function Oxygenases; NADP; Nitrophenols; Oxidoreductases, N-Demethylating; Oxygen; Paclitaxel; Phenacetin; Rats; Sex Factors; Species Specificity; Substrate Specificity; Testosterone

2004
CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.
    Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:8

    Topics: Alleles; Catalytic Domain; Cytochrome P-450 CYP2D6; Dextromethorphan; Ethanolamines; Humans; Imidazoles; Inactivation, Metabolic; Kinetics; Mutation; NADP; Phenotype; Pyrimidines

2018